Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Strategies for Persistent Agitated Delirium in Palliative Care
NCT03743649Phase 3Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2019
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of haloperidol and lorazepam in delirium (4 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Change in Richmond Agitation Sedation Scale score at 24 hours. Started Jul 2019; status: active, not recruiting.
02
Drugs
haloperidollorazepam
03
Conditions
delirium
Beyond the preview
Go deeper on NCT03743649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03743649.